Tumor antigen peptide and use thereof
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Feb 16, 2016
Grant Date -
Aug 18, 2011
app pub date -
Oct 19, 2009
filing date -
Oct 20, 2008
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Disclosed is a peptide consisting of the identical amino acid sequence or a substantially identical amino acid sequence to the amino acid sequence depicted in SEQ ID NO:4, wherein the peptide binds to an HLA antigen and is recognized by cytotoxic T cells. The peptide of the present invention can be used in vivo or in vitro as an agent for inducing CTL, that is, cancer vaccine, and exerts therapeutic or ameliorating effects on tumors such as osteosarcoma, renal cancer, and others. The peptide of the present invention is also useful as a tumor marker directed to tumors such as sarcoma, renal cancer, and others.
First Claim
Family
International Classification(s)
- C07H:SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTI....
- A61K:PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOS....
- C12Q:MEASURING OR TESTING PROCESSES INVOLVING ENZYMES O....
- C12N:MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF
- G01N:INVESTIGATING OR ANALYSING MATERIALS BY DETERMININ....
- C07K:PEPTIDES
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully